Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C)

Maria A. Perez, Hui Mien Hsiao, Xuemin Chen, Amber Kunkel, Nadine Baida, Laila Hussaini, Austin T. Lu, Carol M. Kao, Federico R. Laham, David A. Hunstad, Yajira Beltran, Teresa A. Hammett, Shana Godfred-Cato, Ann Chahroudi, Evan J. Anderson, Ermias Belay, Christina A. Rostad

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Understanding the serological responses to COVID-19 vaccination in children with history of MIS-C could inform vaccination recommendations. We prospectively enrolled seven children hospitalized with MIS-C and measured SARS-CoV-2 binding IgG antibodies to spike protein variants longitudinally pre- and post-Pfizer-BioNTech BNT162b2 primary series COVID-19 vaccination. We found that SARS-CoV-2 variant cross-reactive IgG antibodies variably waned following acute MIS-C, but were significantly boosted with vaccination and maintained for up to 3 months. We then compared post-vaccination binding, pseudovirus neutralizing, and functional antibody-dependent cell-mediated cytotoxicity (ADCC) titers to the reference strain (Wuhan-hu-1) and Omicron variant (B.1.1.529) among previously healthy children (n = 16) and children with history of MIS-C (n = 7) or COVID-19 (n = 8). Despite the breadth of binding antibodies elicited by vaccination in all three groups, pseudovirus neutralizing and ADCC titers were significantly reduced to the Omicron variant.

Original languageEnglish
Pages (from-to)2743-2748
Number of pages6
JournalVaccine
Volume41
Issue number17
DOIs
StatePublished - Apr 24 2023

Fingerprint

Dive into the research topics of 'Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C)'. Together they form a unique fingerprint.

Cite this